Abstract
In spite of the broad popularity of the concept of quality of life in medicine and generally in its broad societal usage, why then is the interest in measuring quality of life in schizophrenia has been somewhat eroded in recent years? Obviously, there is no single answer to such a challenging question, but it seems to relate to a number of issues specific to the schizophrenia disorder itself and its impact on a wide range of mental deficits, as well as the impact of its treatment, i.e., the various and significant side effects of antipsychotic medications. Equally significant is the lack of research interest to go beyond assessments of quality of life into the broader applications that can impact clinical management and other important health outcomes. The excellent contributions to this book by the various internationally known experts in the field, coming from a broad range of theoretical and scientific background, all attest that the concept of quality of life in schizophrenia is alive and continues to be of great interest, but requires to be invigorated. New conceptual thinking, refinement of methodology, and going beyond measurement, into researching models for integration in clinical care as well as in pharmaco- and health economics, are all needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Calman KC. Quality of life in cancer patients – an hypothesis. J Med Ethics. 1984;10:124–7.
Philips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1937–403.
Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - Findings from an in vivo SPECT study. Schizophre Res. 2006;88:178–86.
Voruganti LNP, Awad AG. Role of dopamine in pleasure, reward and subjective responses to drugs – the neuropsychopharmacology of quality of life in schizophrenia. In: Ritsner M, Awad AG, editors. Quality of life impairment in schizophrenia, mood and anxiety disorder. Dordrecht: Springer; 2007. p. 21–31.
Voruganti LNP, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG. Subjective effects of AMPT - induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuro Psychopharmacology. 2001;25:642–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Awad, A.G. (2016). Reinventing Quality of Life: Refining the Concept and Going Beyond Assessments. In: Awad, A., Voruganti, L. (eds) Beyond Assessment of Quality of Life in Schizophrenia. Adis, Cham. https://doi.org/10.1007/978-3-319-30061-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-30061-0_15
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-30059-7
Online ISBN: 978-3-319-30061-0
eBook Packages: MedicineMedicine (R0)